Yoshitaka Tanaka
Directeur Technique/Scientifique/R&D chez NISSUI PHARMACEUTICAL CO., LTD.
Provenance du réseau au premier degré de Yoshitaka Tanaka
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Subsidiary | Medical Specialties | 13 | |
CellGenTech, Inc.
 CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Yoshitaka Tanaka via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Nissui Pharma Medical Sales Co., Ltd.
 Nissui Pharma Medical Sales Co., Ltd. Pharmaceuticals: MajorHealth Technology Nissui Pharma Medical Sales Co., Ltd. engages in the manufacture, sale, import and export of medicine and health foods. The company was founded on June 9, 2016 and is headquartered in Tokyo, Japan. | Pharmaceuticals: Major | Director/Board Member Comptroller/Controller/Auditor Director/Board Member | |
Anaeropharma Science, Inc.
 Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Biotechnology | Director/Board Member | |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Major Banks | Corporate Officer/Principal | |
| Tokyo Institute of Technology | College/University | Graduate Degree | |
Watervein Partners KK
 Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi. | Investment Managers | Private Equity Investor | |
| Nihon University | College/University | Undergraduate Degree | |
| Japan Association of Clinical Reagents Industries | Chairman | ||
| Japanese Committee For Clinical Laboratory Standards | Director/Board Member | ||
| The Federation of Pharmaceutical Manufacturers Assoc of Japan | Director/Board Member | ||
| The Japan Federation of Medical Devices Associations | Director/Board Member | ||
| Toyo University | College/University | Corporate Officer/Principal | |
| LEADER ELECTRONICS CORPORATION | Electronic Equipment/Instruments | Director/Board Member | |
| NISSUI CORPORATION | Food: Meat/Fish/Dairy | Chief Tech/Sci/R&D Officer |
Statistiques
Internationale
| Japon | 13 |
| Etats-Unis | 2 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
| Finance | 3 |
| Electronic Technology | 2 |
| Consumer Non-Durables | 2 |
Opérationnelle
| Director/Board Member | 17 |
| Sales & Marketing | 9 |
| Corporate Officer/Principal | 7 |
| Comptroller/Controller/Auditor | 4 |
| Independent Dir/Board Member | 3 |
Relations les plus connectées
- Bourse
- Insiders
- Yoshitaka Tanaka
- Connexions Sociétés
